As Web's World Turns

[thebign1]

Sold VPHM at $18.10.

I can't complain though. All of my other positions were up big time today.

Hey Webs, Here's one for your buy & hold account.

http://finance.yahoo.com/q/pr?s=VMC

Regards, Norm

[skiracer]

Yea I am holding VPHM, looking to salvage here. I don't know how it happened but it did. I think they had some bad news.

The news regarding VPHM is that an outfit called AKORN and another European pharma company are combining to make a generic copy of VPHM's Vaconin, did I spell that right, drug. This may be a great oportunity for an entry as the two small outfits that are going to try to make the generic copy are not very well capitalized an it take zillions to do what they think they want to do and the time it takes is quite a long time. Can't understand the big drop on this kind of news. Saw it on Briefing.com newswire this morning. Will find it and post it later tonight.

[B.J]

AOB and RWC are way above the 50 day MA. We should get a pullback soon.

So, did you grab any AOB today?

[Websman]

So, did you grab any AOB today?

missed it.

[Websman]

SFCC...ouch. It's a good thing that I just have a small position or it might have hurt real bad. I'm down about 9% from my buy price. I may sell in the morning.

CFK did well for me today and ELN held it's own.

[diogenes]

Sold VPHM at $18.10.

I can't complain though. All of my other positions were up big time today.

Well, my stop was hit , too, on VPHM tuesday.
So, are you still holding out for RWC?

[Websman]

Well, my stop was hit , too, on VPHM tuesday.
So, are you still holding out for RWC?

I'm keeping my limit in to buy RWC at $5.85.

[Websman]

I don't use them a lot, but I placed a stop on CFK. It triggered today, so I'll watch for a pullback.


I have plenty of cash, being my only two positions now are ELN and SFCC.

[jiesen]

I don't use them a lot, but I placed a stop on CFK. It triggered today, so I'll watch for a pullback.


I have plenty of cash, being my only two positions now are ELN and SFCC.

Cash is always good to have. I sometimes (well, ok, always) wish I had more.

[Websman]

Cash is always good to have. I sometimes (well, ok, always) wish I had more.

I said I had plenty of cash, but I could always use more.

[billyjoe]

Webs,
I have lots of assets, but almost no cash waaaaaaaaaaah.

billyjoe

[Lyehopper]

Webs,
I have lots of assets, but almost no cash waaaaaaaaaaah.

billyjoe

I have alot of cows.

Too bad they ain't.... "cash" cows... HAHAHAHAHA!

[Websman]

I dumped SFCC on Friday. This one is too crazy to be holding on to. This was the biggest loser I've had in a while.

I bought AOB at $5.89. I sell this one for $10 or more.


Still holding ELN

[IIC]

I dumped SFCC on Friday. This one is too crazy to be holding on to. This was the biggest loser I've had in a while.

I bought AOB at $5.89. I sell this one for $10 or more.


Still holding ELN

I liked SFCC a few weeks ago...but who needs the controversy???...This is from yesterday:

SFBC International Inc. (SFCC) Chief Executive Arnold Hantman on
Friday defended his drug-testing company against allegations of
threats and coercion raised in a Wednesday news story.

However, the Miami company's stock price, already down more than
24% since the story appeared, fell another 11% Friday.

During the call, Hantman said the Bloomberg News article published
Wednesday, as well as one published by Bloomberg about the drug-
testing industry on Nov. 2, contained misleading statements, as well
as assertions from anonymous sources of threats made by Hantman
himself as well as SFBC employees, that he termed "baseless."

He also said the company's board of directors has hired Thomas Too
of Too Cardness LLP, of Miami, as an independent counsel to review
the allegations and issues raised in the articles and report back to
the board. He said he expects a report within a matter of weeks.

Hantman also said that Thursday afternoon SFBC received a letter
from Sen. Charles Grassley, chairman of the Senate Finance
Committee, asking the company to meet with his committee to discuss
the reported allegations.

But in response to a later question, Hantman said he believes
Grassley's inquiry is looking at how the industry as a whole
conducts clinical trials rather than looking at SFBC alone.

Hantman said the company will cooperate fully with both the
independent counsel and Grassley's committee, as it has "nothing to
hide."

"SFBC believes that there is no merit for the criticism of its
practices, and that the information in both articles is inaccurate,
and that in the second article the information is just untrue,"
Hantman said on the call.

The Bloomberg story contained information from participants in
some of the company's drug trials. Some Latin American immigrants
among the participants allege the company threatened them with
federal deportation for disclosing health risks in clinical trials,
the Bloomberg story said. The participants also said SFBC tried to
make them sign false statements.

The participants said the threats came following the Nov. 2
Bloomberg story, which reported that a number of scientists, doctors
and government officials said the drug-testing industry inadequately
protected participants from the risks of injury and death. SFBC was
included in the article about broader industry practices.

Three drug-trial participants told Bloomberg that the threats were
made by SFBC executives, including Hantman.

A Bloomberg spokeswoman on Wednesday told Dow Jones Newswires that
it stands by the story. (Bloomberg and Dow Jones compete in the
financial news business.)

Co. Understands Why Investors May Be Concerned


On the call, Hantman said the company understands its investors
may be concerned about how the allegations are affecting its
business.

Hantman said based on activity since the first article was
published, the company has "not seen any impact on our existing
contracts, proposals or backlog. And we continue to receive positive
feedback from our clients."

Hantman said the company has contacted Nasdaq regarding unusual
activity in the trading of SFBC in the hours before the second
Bloomberg article appeared.

In response to a question asking why the company doesn't take
legal action against Bloomberg, Hantman said the company
hopes "'regulatory authorities would determine whether or not there
is any action warranted on their behalf."

Hantman said the company asks test subjects to show picture
identification and submits information to the Internal Revenue
Service about any payments it makes. But there is no requirement for
the company to determine U.S. citizenship status before a
participant joins a clinical trial, Hantman said. It does not
withhold Social Security payments because the participants are
independent contractors, he said.

SFBC stock ended Friday's trading session at $23.98, down $2.96,
or 11%.

The stock was trading in the low $40s at the beginning of
November. But it fell 26% on Nov. 3, when the company disclosed an
error in revenue recognition at its PharmaNet unit that produced a
$609,000 overstatement of first-quarter revenue and pretax earnings.
The company said the overstatement was offset by an equal amount of
revenue earned in the third quarter.

[spikefader]

I dumped SFCC on Friday. This one is too crazy to be holding on to. This was the biggest loser I've had in a while.

I bought AOB at $5.89. I sell this one for $10 or more.


Still holding ELN

My uninvited 2c worth dude, your stock picking talent is so good you don't need to be trading stocks that have just had a major weekly channel bust. I've warned about the risks of doing this before. It's a significant thing dude. No question about it. You don't need that kinda risk when your Vulcan eye can pick stocks that are strong.

I think your AOB buy is a good one, now THAT's the kind of weakness you wanna buy! Good luck with it!